The US Food and Drug Administration (FDA) approval of Insmed’s Brinsupri marks a significant advancement in the treatment ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

In the Lancet Respiratory Medicine, Oriol Sibila and colleagues'1 report the results of an innovative study relating baseline symptoms of bronchiectasis with future exacerbations and responses to long ...

British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered ...

The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape.

Among patients with non-cystic fibrosis bronchiectasis, once-daily brensocatib for 52 weeks lowered the annualized pulmonary exacerbation rate and was well tolerated, according to topline results ...

Harris, MD, FCCP discusses Brinsupri™ (brensocatib), a new FDA-approved treatment for non-cystic fibrosis bronchiectasis. Dr ...

Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and ...

HONOLULU — Patients with non-cystic fibrosis bronchiectasis and persistent Aspergillus fumigatus faced a heightened risk for exacerbations, according to research presented at the CHEST ...

According to data from the Bronchiectasis and NTM Registry, the presence of a positive fungal culture in bronchiectasis is not a predictor of more severe disease and has no major impact on outcome.